- Conditions
- Essential Thrombocythemia
- Interventions
- Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Glendale, California • Stanford, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 91
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Chronic
- Interventions
- eltrombopag, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
- Conditions
- Hepatitis C
- Interventions
- Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more
- Conditions
- Kidney Cancer
- Interventions
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- Biological · Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Kidney Cancer
- Interventions
- PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- Thomas Olencki
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Leukemia, Myeloid, Chronic
- Interventions
- Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Melanoma
- Interventions
- Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2031
- U.S. locations
- 3
- States / cities
- San Diego, California • Memphis, Tennessee • Houston, Texas
- Conditions
- Hepatitis C, Chronic
- Interventions
- Viramidine, Peginterferon alfa-2b
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Mateo, California • Bradenton, Florida + 8 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- PEG-IFN-a2b
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- St. Luke's Hospital and Health Network, Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Buffalo, New York • Bethlehem, Pennsylvania + 1 more
- Conditions
- HIV Infections
- Interventions
- Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 16 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 15
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Advanced Cholangiocarcinoma
- Interventions
- Pembrolizumab, Sylatron
- Drug
- Lead sponsor
- Aiwu Ruth He, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Lymphoma
- Interventions
- Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma
- Interventions
- Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV, HIV/AIDS
- Interventions
- Peg-IFN-α2b
- Drug
- Lead sponsor
- The Wistar Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatitis C
- Interventions
- Peg-Intron, REBETOL, HCV 796
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 34
- States / cities
- Anaheim, California • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more
- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- PEGIntron plus ribavirin
- Drug
- Lead sponsor
- Hepatitis Resource Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis C
- Interventions
- Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
- Other · Biological
- Lead sponsor
- Biolex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- PEG-interferon alfa-2b, PEG-interferon alfa-2b
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C
- Interventions
- ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
- Conditions
- HIV Infection
- Interventions
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Hepatitis C
- Interventions
- Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha
- Biological · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C
- Interventions
- Ribavirin, Peg interferon alfa 2b, induction therapy
- Drug
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas